Document is current
Any future updates will be listed below
-
Authors
Tagami, Nami
Uchiyama, Michihiro
Suzuki, Kenshi
Shirai, Heigoroh
Seto, Takeshi
Iida, Shinsuke https://orcid.org/0000-0002-4951-960X
-
Funding
Funding for this research was provided by:
Sanofi K.K.
- License Information
-
More Information
Article History
Received: 13 June 2024
Revised: 5 December 2024
Accepted: 13 December 2024
First Online: 27 December 2024
Declarations
:
: Shinsuke Iida has received lecture fees from Sanofi K.K., Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb K.K., and Pfizer Japan Inc.; trust research/joint research funds from Sanofi K.K., Takeda Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb K.K., Pfizer Japan Inc., Daiichi Sankyo Co. Ltd., Amgen K.K., AbbVie GK, Caelum, Shionogi & Co. Ltd., GlaxoSmithKline K.K., and Celgene; and scholarship funds from Chugai Pharmaceutical Co. Ltd. Kenshi Suzuki has received lecture fees from Takeda Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Amgen K.K., Novartis Pharma K.K., Sanofi K.K., Bristol-Myers Squibb K.K., AbbVie GK, and Janssen Pharmaceutical K.K.; consultancy fees from Amgen K.K., Takeda Pharmaceutical Co. Ltd., and Bristol-Myers Squibb K.K.; and trust research/joint research funds from Bristol-Myers Squibb K.K. Nami Tagami, Heigoroh Shirai, Takeshi Seto and Michihiro Uchiyama have no conflicts of interest to declare.
: The PMS was performed in compliance with the guidelines for GPSP in Japan and the Declaration of Helsinki.
